pentoxifylline has been researched along with Cirrhoses, Experimental Liver in 19 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Oral feeding of yellow phosphorus to pigs reproducibly results in fibrosis after 8 weeks of feeding, extensive fibrosis after 12 weeks and cirrhosis after 16 weeks of yellow phosphorus." | 7.69 | Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanism. ( Neumeister, M; Peterson, TC, 1996) |
| "The effect of PTX on the content of hepatic TGF-beta 1, type I and type III collagen in mice was related to the dosage of PTX." | 5.31 | [Effect of pentoxifylline on the expression of hepatic TGF-beta 1, type I and type III collagen in mice with liver fibrosis due to Schistosoma japonicum infection]. ( Li, SL; Luo, DD; Xiong, LJ; Zeng, LL, 2002) |
| "7%), fibrosis was significantly reduced in the pentoxifylline- and ciprofloxacin-treated groups (4." | 3.70 | Effect of preoperative interventions on outcome following liver resection in a rat model of cirrhosis. ( Gong, Y; Johnson, J; Kneteman, N; Minuk, GY; Moser, M; Zhang, M, 2000) |
| " Oral feeding of yellow phosphorus to pigs reproducibly results in fibrosis after 8 weeks of feeding, extensive fibrosis after 12 weeks and cirrhosis after 16 weeks of yellow phosphorus." | 3.69 | Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanism. ( Neumeister, M; Peterson, TC, 1996) |
| "The effect of PTX on the content of hepatic TGF-beta 1, type I and type III collagen in mice was related to the dosage of PTX." | 1.31 | [Effect of pentoxifylline on the expression of hepatic TGF-beta 1, type I and type III collagen in mice with liver fibrosis due to Schistosoma japonicum infection]. ( Li, SL; Luo, DD; Xiong, LJ; Zeng, LL, 2002) |
| " Long-term administration of pentoxifylline (16 mg/kg orally, 5 days/wk for 12 wk) in an animal model of liver fibrosis prevented elevations in gamma-glutamyl transpeptidase and alkaline phosphatase levels and prevented the reduction in serum albumin level normally observed in this animal model of liver disease." | 1.29 | Pentoxifylline prevents fibrosis in an animal model and inhibits platelet-derived growth factor-driven proliferation of fibroblasts. ( Peterson, TC, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (52.63) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mohamed, DI | 1 |
| Nabih, ES | 1 |
| El-Waseef, DAA | 1 |
| El-Kharashi, OA | 1 |
| Abd El Samad, AA | 1 |
| Toda, K | 1 |
| Kumagai, N | 1 |
| Kaneko, F | 1 |
| Tsunematsu, S | 1 |
| Tsuchimoto, K | 1 |
| Saito, H | 1 |
| Hibi, T | 1 |
| Andrade, Wde C | 2 |
| Tannuri, U | 2 |
| da Silva, LF | 1 |
| Alves, VA | 2 |
| Silva, LF | 1 |
| Coelho, MC | 1 |
| Tannuri, AC | 1 |
| Xiong, LJ | 2 |
| Luo, DD | 2 |
| Zeng, LL | 1 |
| Li, SL | 2 |
| van de Bovenkamp, M | 1 |
| Groothuis, GM | 1 |
| Meijer, DK | 1 |
| Olinga, P | 1 |
| Peterson, TC | 4 |
| Windmeier, C | 1 |
| Gressner, AM | 1 |
| Soupison, T | 1 |
| Yang, S | 1 |
| Bernard, C | 1 |
| Moreau, R | 1 |
| Kirstetter, P | 1 |
| D'Almeida, M | 1 |
| Cailmail, S | 1 |
| Tedgui, A | 1 |
| Lebrec, D | 1 |
| Neumeister, M | 1 |
| Sánchez, S | 1 |
| Albornoz, L | 1 |
| Bandi, JC | 1 |
| Gerona, S | 1 |
| Mastai, R | 1 |
| Park, EJ | 1 |
| Ko, G | 1 |
| Kim, J | 1 |
| Sohn, DH | 1 |
| Oberti, F | 1 |
| Pilette, C | 1 |
| Rifflet, H | 1 |
| Maïga, MY | 1 |
| Moreau, A | 1 |
| Gallois, Y | 1 |
| Girault, A | 1 |
| le Bouil, A | 1 |
| Le Jeune, JJ | 1 |
| Saumet, JL | 1 |
| Feldmann, G | 1 |
| Calès, P | 1 |
| Isbrucker, RA | 1 |
| Rowden, G | 1 |
| Desmoulière, A | 1 |
| Xu, G | 1 |
| Costa, AM | 1 |
| Yousef, IM | 1 |
| Gabbiani, G | 1 |
| Tuchweber, B | 1 |
| Moser, M | 1 |
| Zhang, M | 1 |
| Gong, Y | 1 |
| Johnson, J | 1 |
| Kneteman, N | 1 |
| Minuk, GY | 1 |
| Raetsch, C | 1 |
| Jia, JD | 1 |
| Boigk, G | 1 |
| Bauer, M | 1 |
| Hahn, EG | 1 |
| Riecken, EO | 1 |
| Schuppan, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487] | Phase 2 | 17 participants (Actual) | Interventional | 2013-02-04 | Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | U/L (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 160 |
The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 0 |
| Group 2 | 0 |
The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 6 |
| Pentoxifylline - Group 2 | 0 |
The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | 10^3 Platelets/μL (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 208 |
"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age
| Intervention | cm (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 10.0 |
The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes
| Intervention | days (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 317 |
| Pentoxifylline - Group 2 | 273 |
19 other studies available for pentoxifylline and Cirrhoses, Experimental Liver
| Article | Year |
|---|---|
The protective effect of pentoxifylline versus silymarin on the pancreas through increasing adenosine by CD39 in a rat model of liver cirrhosis: Pharmacological, biochemical and histological study.
Topics: Adenosine; Amylases; Animals; Antigens, CD; Apyrase; Disease Models, Animal; Insulin-Secreting Cells | 2018 |
Pentoxifylline prevents pig serum-induced rat liver fibrosis by inhibiting interleukin-6 production.
Topics: Administration, Oral; Animals; Cell Proliferation; Cells, Cultured; DNA Replication; Dose-Response R | 2009 |
Effects of the administration of pentoxifylline and prednisolone on the evolution of portal fibrogenesis secondary to biliary obstruction-an experimental study in growing animals.
Topics: Animals; Biliary Atresia; Biliary Tract Diseases; Cholestasis; Common Bile Duct Diseases; Disease Mo | 2009 |
Effects of the administration of pentoxifylline and prednisolone on the evolution of portal fibrogenesis secondary to biliary obstruction in growing animals: immunohistochemical analysis of the expression of TGF-β and VEGF.
Topics: Animals; Cholestasis; Disease Models, Animal; Glucocorticoids; Immunohistochemistry; Liver; Liver Ci | 2012 |
[Effect of pentoxifylline on the expression of hepatic TGF-beta 1, type I and type III collagen in mice with liver fibrosis due to Schistosoma japonicum infection].
Topics: Animals; Collagen Type I; Collagen Type III; Dose-Response Relationship, Drug; Female; Liver; Liver | 2002 |
Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro.
Topics: Actins; Animals; Benzamides; Biomarkers; Collagen; Collagen Type I; Collagen Type I, alpha 1 Chain; | 2006 |
[A study on the antifibrosis effects of pentoxifylline in treating schistosomiasis japonica mice with liver fibrosis].
Topics: Animals; Female; Liver Cirrhosis, Experimental; Mice; Mice, Inbred Strains; Pentoxifylline; Schistos | 2008 |
Pentoxifylline prevents fibrosis in an animal model and inhibits platelet-derived growth factor-driven proliferation of fibroblasts.
Topics: Animals; Cell Division; Cells, Cultured; Collagen; Female; Fibroblasts; gamma-Glutamyltransferase; L | 1993 |
Effect of pentoxifylline on the fibrogenic functions of cultured rat liver fat-storing cells and myofibroblasts.
Topics: Adipocytes; Animals; Cell Differentiation; Cell Division; Cells, Cultured; Extracellular Matrix Prot | 1996 |
Acute haemodynamic responses and inhibition of tumour necrosis factor-alpha by pentoxifylline in rats with cirrhosis.
Topics: Animals; Hemodynamics; Liver Cirrhosis, Experimental; Male; Pentoxifylline; Portal Pressure; Rats; R | 1996 |
Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanism.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Bile Ducts; Cell Division; Collagen; Dis | 1996 |
Pentoxifylline, a drug with rheological effects, decreases portal pressure in an experimental model of cirrhosis.
Topics: Animals; Blood Viscosity; Cardiac Output; Cholestasis; Disease Models, Animal; Double-Blind Method; | 1997 |
Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction.
Topics: Animals; Basidiomycota; Body Weight; Cholestasis; Common Bile Duct Diseases; Female; Glycyrrhetinic | 1997 |
Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation.
Topics: Animals; Bile Ducts; Blood Pressure; Double-Blind Method; Hemodynamics; Hypertension, Portal; Hypoli | 1997 |
Platelet-derived growth factor and pentoxifylline modulation of collagen synthesis in myofibroblasts.
Topics: Animals; Collagen; Female; Liver; Liver Cirrhosis, Experimental; Monocytes; Pentoxifylline; Platelet | 1998 |
Drug-metabolizing enzymes in rat liver myofibroblasts.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Benz(a)Anthracenes; Cells, Cultured; Cytochrome P-450 CYP1A1 | 1998 |
Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells.
Topics: Acetone; Animals; Bile Ducts; Carbon Tetrachloride Poisoning; Cell Differentiation; Cell Division; C | 1999 |
Effect of preoperative interventions on outcome following liver resection in a rat model of cirrhosis.
Topics: Animals; Anti-Infective Agents; Aspartate Aminotransferases; Bilirubin; Ciprofloxacin; Diagnosis, Co | 2000 |
Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis.
Topics: Administration, Oral; Animals; Cholestasis; Chronic Disease; Collagen; Cytokines; DNA Probes; DNA, C | 2002 |